Thank you for your patience while your study has been under peer-review. We have now received reports from the three referees that were asked to assess it, which can be found at the end of this email. As you will see, all the referees find the topic of interest and in principle suitable for us, although they all mention the work is currently insufficiently developed for publication here in its present form.
As their reports are pasted below, I will not go into details here. However, there are three important aspects that need strengthening during revision that I would like to emphasize. Biochemically, please address whether Alfy's FIFV motif could be a LIR/CLIR hybrid, as suggested by referee 1. I feel this possibility would give the field a new point of view that could be important. From a functional perspective, more evidence for the GABARAP-mediated recruitment of ALFY to LC3-positive structures is required, as is proof of the physiological relevance of the ALFY LIR:GABARAP interaction. Addressing these issues would be necessary for publication in EMBO reports, given our emphasis on the functional and physiological relevance of the findings we publish. In addition, please address the other minor issues raised in the reviews.
If the referee concerns can be adequately addressed, we would be happy to accept your manuscript for publication. However, please note that it is EMBO reports policy to undergo one round of revision only and thus, acceptance of your study will depend on the outcome of the next, final round of peer-review.
Revised manuscripts must be submitted within three months of a request for revision unless previously discussed with the editor; they will otherwise be treated as new submissions. Revised manuscript length must be a maximum of 29,000 characters (including spaces). When submitting your revised manuscript, please also include editable TIFF or EPS-formatted figure files, a separate PDF file of any Supplementary information (in its final format) and a letter detailing your responses to the referees.
We also welcome the submission of cover suggestions or motifs that might be used by our Graphics Illustrator in designing a cover.
I look forward to seeing a revised form of your manuscript when it is ready. In the meantime, do not hesitate to get in touch with me if I can be of any assistance.
REFEREE REPORTS:
Referee #1 (Report):
Lystad et al discovered that ALFY binds selectively certain orthologs of ATG8, namely Gabaraps and LC3C but not LC3A and LC3B. They identified the binding site in Alfy and solved the crystal structure of an Alfy peptide in complex with GABARAP. Their crystal structure explains why only certain ATG8 orthologs bind Alfy, as certified by the authors' ability to mutate LC3B into an Alfy ligand. This is certainly an interesting paper that contributes to the emerging theme of specific binding partners for individual members / subsets of the ATG8 family. However, the manuscript falls somewhat short of taking into account recent developments in this field. In particular, the authors interpret their data under the assumption there is only one type of LIR motif (W/F/YxxI/L/V). They thereby ignore that an LC3C-specific variant LIR (xLVV), termed CLIR, has been discovered (von Muhlinen, Mol Cell 2012) . Interestingly enough, the FIFV motif in Alfy could represent a 'hybrid' between the two known binding motifs as it contains an aromatic residue in position 1 and hydrophobic residues in position 2 and 3. In addition, given that the structure of the LC3C-specific CLIR of NDP52 has been solved and specificity determinants identified, statements such as 'structural determinants for ... selectivity largely remain to be determined' should be modified.
1. Fig1a: Characterization of binding specificity is not systematic. The authors are therefore encouraged to test all ATG8 orthologs in parallel. It would also be helpful to determine the Kd for the interaction with strong (GBR, GBPL1) and weak binders (LC3C, GBRL2). 2. Given the contribution of residues 2 and 3 in the CLIR xLVV motif, are the corresponding residues in Alfy of importance? 3. The authors identified K24, Y25, D54 as contributing to the specific binding of GBR to Alfy. Some of the corresponding residues in LC3C are important for its specific binding to NDP52 (von Muhlinen 2012), which might be worth discussing in the context of how ATG8 orthologs provide specific binding surfaces for their cognate receptors. 4. The authors claim that binding to GABARAP family members is required for the recruitment of Alfy to LC3B structures. This is an overinterpretation unless the authors can exclude recruitment via LC3C.
Referee #2 (Report):
In the current manuscript Lystad et al describe structural determinants important for direct interaction between Atg8-like proteins and ALFY. The authors identified a LIR domain in ALFY and specific amino acids in the GABARAP subfamily and LC3C that are important for the interaction with ALFY. In addition, the authors utilized crystallography to determine the structure of GABARAP-ALFY peptide. According to the proposed model, these structural determinants contribute to the differential binding within the Atg8s to ALFY, in favor of GABARAPs and LC3C.
The manuscript is well written and the results are mostly convincing, however there are several issues that need the authors' attention. To further support their proposed model whereby GABARAP mediates the recruitment of ALFY to LC3-positive structures, the authors should directly assess the role of GABARAP in this process. The differences between LC3C and LC3A/B isoforms with regard to ALFY association should be demonstrated more clearly. Most importantly, the manuscript lacks data regarding physiological relevance of the findings. The significance of the identified domains for ALFY's function, for example in autophagic clearance of protein aggregates, should be examined. Additional comments: Figure 1A : Total cell lysates should be presented. Figure 1D : It is hard to conclude that LC3C binds ALFY more efficiently than LC3A/B. Figure 4B : To allow better interpretation of the results, images of both green and red channels should be presented separately.
Referee #3 (Report):
In the process of autophagy, a membrane sac called the autophagosome sequesters material to be transported to and degraded in the lysosome. Autophagosome formation requires a unique set of proteins called Atg, among which Atg8 family proteins play crucial roles in multiple steps, including autophagosomal membrane formation and the selective incorporation of specific cargos into the autophagosome. Mammalian cells have seven Atg8 homologs, and their functional difference is one of the recent hot topics in the autophagy research filed. In this report, Lystad et al. clearly showed that ALFY, which interacts with phosphatidylinositol 3-phosphate and the autophagic receptor p62 to mediate degradation of poly-ubiquitinated protein aggregates by autophagy, specifically binds to GABARAP subfamily proteins and LC3C among Atg8 homologs. The authors identified a motif called the LC3-interacting region (LIR) in the WD40 region in ALFY, and determined the structure of GABARAP and the LIR motif peptide from ALFY. Together with biochemical analyses with mutant proteins, the authors revealed a unique interaction mode between GABARAP and ALFY, which elegantly explains how ALFY specifically interacts with a subset of Atg8 homologs including GABARAP. However, this work leaves a very critical issue to be examined: whether this interaction is important for the autophagic clearance of polyubiquitinated protein aggregates. This major point should be addressed for the acceptance of this study for publication in EMBO reports.
Minor comments: (1) I wonder how the existence of a LIR motif in the WD40 region (not in the other domains) is linked to the function of ALFY. Do the authors have some idea about this question?
(2) (Figure 2A ) Only a Drosophila ALFY homolog (Blue Cheese) shows a much less homology compared to the other homologs. A reference showing that this protein is a true homolog of ALFY should be cited. The authors should also mention which Atg8 homolog is most closely related to dAtg8a.
(3) ( Figure 3B ) Although the authors describe in the text that both LC3B and GABARAP form the major interaction sites for F3346 and V3349, it is difficult to understand this from the present figure. The authors also describe that tyrosine (Y3351 of ALFY) and histidine (H57 of LC3B) cause electrostatic repulsion. I am afraid I just don't know it, but is this correct? (4) As a complementary experiment to those shown in Figures 3D-F , it would be better to examine if mutations at K3343, D3344 and Y3351 also allow ALFY to bind to LC3B.
(5) In the main text, based on the result shown in Figure 4C , the authors discuss that ALFY may function upstream of Atg8 proteins, but I cannot understand the logic of this. We would like to thank the reviewer for the constructive comments and criticism which have significantly improved the revised manuscript.
It was not our intention to ignore the existence of the CLIR motif as reported by von Muhlinen et al. The possibility of ALFY containing a hybrid LIR/CLIR is very interesting, but something we did not consider initially as the binding to LC3C is so weak compared to binding of ALFY to GABARAPs. However, we have now tested this possibility experimentally (see response to point 2 below) and have also included a description of the CLIR of NDP52 in the introduction (top p4) and the results (bottom p7). Moreover, we have modified the statement stating that such determinants ' …largely remain to be determined' (bottom p3).
Fig1a: Characterization of binding specificity is not systematic. The authors are therefore encouraged to test all ATG8 orthologs in parallel. It would also be helpful to determine the Kd for the interaction with strong (GBR, GBPL1) and weak binders (LC3C, GBRL2).
We have repeated the pulldown experiments with all human Atg8 orthologs (LC3A, LC3B, LC3C, GABARAP, GABARAPL1 and GABARAPL2) expressed as GFP-tagged proteins (new Fig. 1a ) and have also done direct interaction experiments where recombinant ALFY (aa 2981-3526) was incubated with GSTtagged Atg8 proteins (new Fig. 1D ). Both experimental set-ups showed that ALFY interact strongly with the GABARAPs and very weakly with LC3C. Little or no binding to LC3A and LC3B were detected. Further, based on the suggestion by Reviewer #1, we performed ITC experiments to determine the binding affinities (new Fig. 2D and supplementary Fig 1D) . The ITC experiments revealed that the binding affinity of the ALFY LIR-peptide to the GABARAPs was much higher compared with that to LC3C (GABARAP: 0,327 uM, GABARAPL1: 0, 387 uM, GABARAPL2: 0, 871 uM, LC3C: 20, 8 uM) . In agreement with our other binding assays, there was no detectable binding to LC3B.
Given the contribution of residues 2 and 3 in the CLIR xLVV motif, are the corresponding residues in Alfy of importance?
We have made individual point-mutations of the F3346, I3347, F3348 and V3349 residues in the ALFY LIR/CLIR motif of GFP-ALFY (2981-3526). These mutants, as well as the wild type, were in vitro-translated and incubated with GST-GABARAP or -LC3C, and the binding was evaluated by autoradiography (ARG) (new Fig. 2B We agree with the reviewer that this is an interesting and important point to discuss and this is now included (bottom p7), text reading: "Moreover, the corresponding residues in LC3C (K32/F33/E63) are similar to the GABARAP subfamily ( Fig 3C) and have been implicated in the specific binding to NDP52 [3] ."
The authors claim that binding to GABARAP family members is required for the recruitment of Alfy to LC3B structures. This is an overinterpretation unless the authors can exclude recruitment via LC3C.
In Fig.4B (ALFY KO mouse embryonic fibroblasts) and Suppl Fig. 5B (HeLa cells) we provided data showing that the ALFY LIR motif is required for colocalization of ALFY with GABARAP-and LC3-positive structures upon starvation. Since the ALFY-LIR mutant did not colocalize with either GABARAP or LC3B, and did not bind to LC3B, we concluded that the colocalization of ALFY-LC3B depends on binding of ALFY to GABARAP. The reviewer #1 raised a possibility that this could in principle be recruitment via LC3C. However, as mouse does not have LC3C and digital PCR analysis showed that there is no expression of LC3C in HeLa cells (new suppl. Fig.5A ), we made the same conclusion in the revised manuscript. In addition, we showed that ALFY-p62 positive structures negative for LC3B accumulate in HeLa cells depleted of the GABARAPs, whereas ALFY-p62-LC3B positive structures were detected in control cells (new Fig.4C ). Interestingly, p62-and LC3B-positive puncta lacking ALFY could be detected in siGABARAP cells, indicating that a subset of p62-positive structures localizes with LC3B in the absence of GABARAP, but that recruitment of LC3B to ALFY-p62 positive bodies requires GABARAP. We also included western blots from control/siALFY HeLa cells (new Fig.4D ), as well as wt and ALFY KO MEFs (new Fig.4E) , showing that whereas p62 accumulates in the TX-100 insoluble fraction upon proteotoxic stress and inhibited autophagic flux (BafA1 treated) in control cells, this is prevented in cells lacking ALFY. As p62-positive structures were still detected (by immunofluorescence microscopy) in ALFY deficient cells, we would argue that ALFY recruits a subset of p62 structures for degradation by autophagy through its GABARAPmediated recruitment of LC3B-positive autophagic membranes. A schematic model is presented in Fig 3F . We would like to thank the reviewer for the constructive comments and criticism which have significantly improved the revised manuscript.
To further support their proposed model whereby GABARAP mediates the recruitment of ALFY to LC3-positive structures, the authors should directly assess the role of GABARAP in this process.
Our previous model was based on data in Fig.4B (ALFY KO mouse embryonic fibroblasts) and Suppl Fig.  5B (HeLa cells) showing that the ALFY LIR motif is required for colocalization of ALFY with LC3-positive structures upon starvation. As ALFY did not bind to LC3B, we concluded that the colocalization of ALFY with LC3B requires binding of the ALFY LIR motif to GABARAP. As suggested by the reviewer, we have now strengthened this model by providing data showing that ALFY-p62 positive structures negative for LC3B accumulated in HeLa cells depleted of the GABARAPs, whereas ALFY-p62-LC3B positive structures were detected in control cells (new Fig.4C ). Interestingly, ALFY-negative p62-and LC3B-positive puncta were detected in siGABARAP cells, indicating that p62 can still interact with LC3 in the absence of GABARAP, but that recruitment of LC3 to ALFY-p62 positive bodies requires GABARAP. We have excluded the involvement of LC3C in this process because LC3C is absent in mice and is not expressed in HeLa cells (new suppl. Fig.5A ).
The differences between LC3C and LC3A/B isoforms with regard to ALFY association should be demonstrated more clearly.
We agree that this difference was not so obvious from in the first submitted manuscript. We have therefore repeated the GFP pulldown experiments with all human Atg8 homologs (LC3A, LC3B, LC3C, GABARAP, GABARAPL1 and GABARAPL2) expressed as GFP-tagged proteins (new Fig. 1A ) and have also done direct interaction experiments where recombinant ALFY (aa 2981-3526) was incubated with GSTtagged Atg8 proteins (new Fig. 1D ). Both experimental set-ups showed that ALFY interacts strongly with the GABARAPs and very weakly with LC3C. Little or no binding to LC3A and LC3B were detected. These results were in good agreement with data from Isothermal Titration Calorimetry (ITC) experiments to determine the individual binding affinities (new Fig. 2D and supplementary Fig S1D) . The ITC experiments revealed that the binding affinity of the ALFY LIR-peptide to the GABARAPs was quite higher compared with that to LC3C (GABARAP: 0,327 uM, GABARAPL1: 0,387 uM, GABARAPL2: 0,871 uM, LC3C: 0,8 uM).
In agreement with our other binding assays, there was no detectable binding to LC3B.
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Most importantly, the manuscript lacks data regarding physiological relevance of the findings. The significance of the identified domains for ALFY's function, for example in autophagic clearance of protein aggregates, should be examined.
In addition to the experiments described above, we have included western blots from control/siALFY HeLa cells (new Fig.4D ), as well as wt and ALFY KO MEFs (new Fig.4E) , showing that whereas p62 accumulates in the TX-100 insoluble fraction upon proteotoxic stress and inhibited autophagic flux (BafA1 treated) in control cells, this is prevented in cells lacking ALFY. As p62-positive structures were still detected (by immunofluorescence microscopy) in ALFY deficient cells, we would argue that ALFY recruits a subset of p62 structures for degradation by autophagy. Moreover, there was no recruitment of LC3 to ALFY-p62-positive structures in cells depleted of GABARAP, although colocalization of p62 and LC3 in spots negative for ALFY was observed. Thus, our data suggest that ALFY is required for autophagic clearance of a subset of p62 bodies through its GABARAP-mediated recruitment of LC3-positive autophagic membranes. A schematic model is presented in Fig 3F .
We have tried very hard to rescue the function of endogenous ALFY (depleted with siRNA in HeLa cells or using ALFY KO MEFs) in p62 body clearance (as well as in clearance of Huntingtin aggregates) with ectopic expression of ALFY having a wild type or mutant LIR motif, without success. To overexpress the full length ALFY wild type or LIR mutant construct we have to use an adenovirus system, which yielded very low amounts of vector and low expression levels of this huge protein (405 kDa), making it nearly impossible to rescue aggregate-clearance in a quantitative biochemical assay. Expression levels of mCherry-tagged ALFY (2285-3526) wt or LIR mutant was good, but as this construct only contains the Cterminal one third of the protein it is very likely that the remaining protein is required to rescue the effect of ALFY depletion.
Additional comments:
Figure 1A: Total cell lysates should be presented. This has now been included. We would like to thank the reviewer for the constructive comments and criticism which have significantly improved the revised manuscript.
However, this work leaves a very critical issue to be examined: whether this interaction is important for the autophagic clearance of poly-ubiquitinated protein aggregates. This major point should be addressed for the acceptance of this study for publication in EMBO reports.
In the previous version of the manuscript we presented evidence that the ALFY LIR motif is required for colocalization of ectopically expressed ALFY with LC3-positive structures in ALFY KO mouse embryonic fibroblasts (Fig.4B ) and in ALFY-depleted HeLa cells (Suppl Fig. 5B ). As ALFY did not bind to LC3A/B and no LC3C was expressed in these cells (new suppl. Fig.5A ), we concluded that colocalization of ALFY with LC3B requires binding of the ALFY LIR motif to GABARAP. In order to investigate whether this interaction is required for the autophagic clearance of poly-ubiquitinated protein aggregates, we have used several approaches. First, we showed that whereas ALFY-p62-LC3-positive structures are detected in control cells, there is no recruitment of LC3 to ALFY-p62-positive structures in cells depleted of GABARAP (new Fig.4C ). Interestingly, ALFY-negative p62-and LC3B-positive puncta were detected in siGABARAP cells, indicating that p62 can still interact with LC3 in the absence of GABARAP, but that recruitment of LC3 to ALFY-p62 positive bodies requires GABARAP. We also included western blots from control/siALFY HeLa cells (new Fig.4D ), as well as wt and ALFY KO MEFs (new Fig.4E) , showing that whereas p62 accumulates in the TX-100 insoluble fraction upon proteotoxic stress and inhibited autophagic flux (BafA1 treated) in control cells, this is prevented in cells lacking ALFY. As p62-positive structures were still detected (by immunofluorescence microscopy) in ALFY deficient cells, we would argue that ALFY recruits a subset of p62 structures for degradation by autophagy through its GABARAP-mediated recruitment of LC3-positive autophagic membranes. A schematic model is presented in Fig 3F. We have tried very hard to rescue the function of endogenous ALFY (depleted with siRNA in HeLa cells or using ALFY KO MEFs) in p62 body clearance (as well as in clearance of Huntingtin aggregates) with ectopic expression of ALFY having a wild type or mutant LIR motif, without success. To overexpress the full length ALFY wild type or LIR mutant construct we use an adenovirus vector, which yielded very low amounts of vector and low expression levels of this huge protein (405 kDa), making it nearly impossible to rescue aggregate-clearance in a quantitative biochemical assay. Expression levels of mCherry-tagged 8 ALFY (2285-3526) wt or LIR mutant was good, but as this construct only contains the C-terminal one third of the protein it is very likely that the remaining protein is required to rescue the effect of ALFY depletion.
Minor comments:
I wonder how the existence of a LIR motif in the WD40 region (not in the other domains) is linked to the function of ALFY. Do the authors have some idea about this question?
In addition to the function described above (ALFY-LIR-mediated recruitment of LC3 to p62-positive protein aggregates), we speculate that ALFY may scaffold the Atg5-Atg12-Atg16L1 complex known to facilitate lipidation of Atg8 proteins. This is based on previous findings that the WD40 region of ALFY mediates its colocalization and interaction with ATG5 (Filimonenko et al, Mol Cell 2010) .
2. (Figure 2A) We have included a reference to Finley et al, J. Neuroscience, 2003 , showing that flies lacking Blue Cheese are characterized by accumulation of ubiquitin-positive aggregates in their brain. We also now mention that the dAtg8 is most closely related to human GABARAP (p6).
(Figure 3B) Although the authors describe in the text that both LC3B and GABARAP form the major interaction sites for F3346 and V3349, it is difficult to understand this from the present figure. The authors also describe that tyrosine (Y3351 of ALFY) and histidine (H57 of LC3B) cause electrostatic repulsion. I am afraid I just don't know it, but is this correct?
We agree with the reviewer that it is not possible from Fig.3B to see that the hydrophobic pockets of both LC3B and GABARAP form the major interaction sites of F3346 and V3349 in the ALFY LIR. However, as the main point of this figure is to show that residues outside the hydrophobic pockets (K24/Y25/D54 of GABARAP, Q26/H27/H57 of LC3B) interact differently with the ALFY LIR-peptide, and we later show that the LC3B triple mutant (Q26K/H27Y/H57D) is able to bind to ALFY, we decided to keep the figure and have modified the text (p7). For showing the interactions of F3346 and V3349 with two hydrophobic pockets, we presented a stick model of ALFY core LIR on the surface of GABARAP (new supplementary Fig 2B) .
We are sorry for our misinterpretation of the data. There is no electrostatic repulsion between Y3351 of Alfy and His57 of LC3B. Rather, there is steric hindrance due to the close proximity of the two side chains. This statement has now been corrected (p7). Figures 3D-F , it would be better to examine if mutations at K3343, D3344 and Y3351 also allow ALFY to bind to LC3B.
As a complementary experiment to those shown in
We would like to thank the reviewer for this suggestion. We have now done the experiments and as can be seen in new Fig.3G , mutation of these residues (K3343, D3344 and Y3351) in ALFY (2981-3526) resulted in its loss of binding to GABARAP, while no increased binding to LC3B was detected. This further support our data with the GABARAP and LC3B triple mutants, indicating that the ALFY residues K3343/D3344/Y3351 engage in interactions with K24/Y25/D54 of GABARAP, rather than preventing an interaction with LC3B. Figure 4C , the authors discuss that ALFY may function upstream of Atg8 proteins, but I cannot understand the logic of this.
In the main text, based on the result shown in
This figure (Fig.4C of the original submission, suppl. Fig.6B in revised version) showed that ALFY depletion has no effect on starvation-induced processing of LC3B or GABARAP and we therefore concluded that ALFY function upstream of Atg8 proteins. We agree that the use of 'upstream' in this context is misplaced, as we rather believe that the ALFY-GABARAP interaction is important for selective autophagy of aggregate-prone proteins. We have therefore deleted this statement and simply write "However, in line with our previous data, depletion of ALFY did neither affect the total level, the lipidation nor the turnover of Atg8 proteins (LC3B, GABARAP and GABARAPL1) in response to starvation." (p10). Thank you for your patience while we have reviewed your revised manuscript. As you will see from the reports below, the referees are now all positive about its publication in EMBO reports, although referee 1 has some outstanding minor concerns regarding the discussion of canonical LIR vs CLIR motif and the LC3C expression data.
I am therefore very happy to write with an 'accept in principle' decision, which means that we will accept your manuscript for publication once these referee concerns have been dealt with and a few minor issues/corrections have been addressed, as follows.
-At over 31,800 characters, your study is longer than we can normally accommodate. I would not want you to spend too long on this, but perhaps you could go through the text once more and use a more succinct style without losing information? If you can shorten it to less than 30,000 characters, this would be great. However, please note that the Materials & Methods section cannot be any shorter.
-We now encourage the publication of original source data -particularly for electrophoretic gels and blots, but also for graphs-with the aim of making primary data more accessible and transparent to the reader. If you agree, you would need to provide one PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures and an Excel sheet or similar with the data behind the graphs. The files should be labeled with the appropriate figure/panel number, and the gels should have molecular weight markers; further annotation could be useful but is not essential. The source files will be published online with the article as supplementary "Source Data" files and should be uploaded when you submit your final version. If you have any questions regarding this please contact me.
After all remaining corrections have been attended to, you will receive an official decision letter from the journal accepting your manuscript for publication in the next available issue of EMBO reports. This letter will also include details of the further steps you need to take for the prompt inclusion of your manuscript in our next available issue.
motif and not a CLIR motif? In addition, it has been shown that introducing an aromatic residue into position 1 of xLVV enhances binding; mutating it in a potential hybrid LIR / CLIR would weaken binding, as observed by the authors. Therefore, in my opinion, these data are fully consistent with the idea of a hybrid LIR / CLIR motif and do not support the authors' conclusions about LIR-type and not CLIR-type binding. However, given the new binding data demonstrating only very, very weak LC3C binding I personally would not put too much weight on this aspect of the manuscript any longer.
p9:
The authors find that LC3C is not expressed in HeLa and 293 cells (FigS5).
LC3C is a widely expressed gene (http://biogps.org/#goto=genereport&id=440738) and it has been detected in Hela at levels roughly similar to other ATG8 orthologs (FigS1D, von Muhlinen, Mol Cell) . Are the authors confident that their Hela and 293 really do not express LC3C? Do the authors have a positive control for the performance of their LC3C primers?
Referee #2:
The authors addressed most of my and the other reviewers comments from the first round and in its present form the manuscript meets the scientific merit of Embo Reports.
Referee #3:
In the revised manuscript, the authors have satisfactorily addressed all the concerns I raised in the first round of review. I think the present manuscript is acceptable for publication in EMBO reports. I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports. Thank you for your contribution to our journal.
As part of the EMBO publication's Transparent Editorial Process, EMBO reports publishes online a Review Process File to accompany accepted manuscripts. As you are aware, this File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
If you do NOT want this File to be published, please inform the editorial office within 2 days, if you have not done so already, otherwise the File will be published by default [contact: emboreports@embo.org]. If you do opt out, the Review Process File link will point to the following statement: "No Review Process File is available with this article, as the authors have chosen not to make the review process public in this case."
Thank you again for your contribution to EMBO reports and congratulations on a successful publication. Please consider us again in the future for your most exciting work.
